Revolution's pancreatic cancer drug doubles survival, boosts quality of life - Reuters

Chronological Source Flow
Back

AI Fusion Summary

Revolution’s new drug daraxonrasib has nearly doubled survival rates for some advanced pancreatic cancer patients, according to a study, and also improved their quality of life, demonstrating significant progress in treating this aggressive disease.
Community Comments
Loading updates...
0